Neurogene stops Batten gene therapy after FDA denies request, dealing double dose of bad news Read more 

Incyte's $750M buyout rocked by pause on key trial, asset cull Read more 

Nearing potential FDA approval, BridgeBio shows additional positive data on ATTR-CM candidate acoramidis Read more 

Munich

BayOConnect 2025

BayOConnect serves as a central platform, uniting visionary thinkers, innovative companies, and life science enthusiasts from the Bavarian biotech landscape and across the globe. Its [...]

Go to Top